Roche announced that it has expanded collaboration with Janssen Biotech (Janssen) to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.
New agreement expands activities to include a wide-range of companion diagnostics, including tissue and blood-based biomarkers, sequencing and digital pathology.
The collaboration is based on a commitment to individualised healthcare, expanding the availability of diagnostics to enable patient-directed treatment options.
The new, expanded agreement broadens opportunities for Roche and Janssen to collaborate in the precision medicine field with multiple companion diagnostics technologies, including immunohistochemistry (IHC), digital pathology, next generation sequencing, polymerase chain reaction and immunoassays
